· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
March 8, 2011
Subject: RECALL of Lot JEV09L37C IXIARO® Japanese Encephalitis vaccine (inactivated, adsorbed)
Dear Health Care Professional,
Intercell AG and Novartis Pharmaceuticals Canada Inc. (Novartis), in consultation with Health Canada, are asking Canadian health care professionals to immediately stop using lot JEV09L37C of IXIARO® (Japanese Encephalitis vaccine (inactivated, adsorbed)), DIN 02333279, UPC Code 0 63601 18546 0.
Following a review of potency tests at the 11-month stability time point for lot JEV09L37C, Intercell AG and Novartis, in consultation with Health Canada, have concluded that this specific lot, when administered after December 23, 2010 may be less potent and not induce a full protective immune response in vaccinees. Therefore, lot JEV09L37C IXIARO® is being recalled in Canada.
Consistent with this decision to recall lot JEV09L37C IXIARO®, Novartis is asking Canadian health care professionals and distributors to return any unused doses of IXIARO® from lot JEV09L37C for suitable credit.
Lot JEV09L37C IXIARO® met all quality specifications at time of release and, with the exception of the potency test, all other stability tests were within the requirements. No other lots of IXIARO® are affected by this recall.
Customers who currently have inventory of lot JEV09L37C IXIARO® are advised:
IXIARO® is manufactured by Intercell AG and distributed in Canada by Novartis. Intercell AG and Novartis reiterate their commitment to the delivery of quality pharmaceutical products.
Managing marketed health product-related adverse reactions is dependent upon health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse events in patients receiving IXIARO® should be reported to your local public health authorities. Reports may also be sent directly to the Public Health Agency of Canada or Novartis or Health Canada at the following addresses:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.,
Dorval, QC H9S 1A9
e-mail address: drug.safety@novartis.com
Public Health Agency of Canada
Vaccine Safety Section
130 Colonnade Road,
Address Locator: 6502A
Ottawa, ON K1A OK9
Telephone: 1-866-844-0018
Fax: 1- 866-844-5931
caefi@phac-aspc.gc.ca
How to report a suspected Adverse Event following Immunization:
If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form and send it to the local health department in your province or territory. The list of contacts is also provided below.
If you have any questions or have difficulties contacting your local health department, please contact the Vaccine Safety Section at the Public Health Agency of Canada at:
Telephone: 613-954-5590, 1-866-844-0018
Fax: 613-954-9874; 1-866-844-5931
You can also report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Biologics and Genetic Therapies Directorate (BGTD)
E-mail: BGTD_ORA_Enquiries@hc-sc.gc.ca
Telephone: 613-957-1722
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
We regret any inconvenience this might cause, however, should you have any questions regarding returns, your account or to place an order, please contact Novartis Customer Relations at 1-800-465-2244
Should you require additional medical information regarding the use of IXIARO®, please contact Novartis Medical Information at 1-800-363-8883
Sincerely,
original signed by
Kerstin Westritschnig, M.D.
Medical Officer
Intercell AG
Jean-Marie Leclerc, M.D., FRCP(C)
Chief Scientific Officer and Senior Vice-President
Clinical and Regulatory Affairs
Novartis Pharmaceuticals Canada Inc.
IXIARO® is a registered trademark.
Provincial/Territorial Contacts for Adverse Events Following Immunization Form